| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Observatory of Prolymphocytic Leukemia T NCT04411043 | French Innovative Leukemia Organisation | — |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03185494 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 an NCT03097770 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636 | Masonic Cancer Center, University of Minnesota | N/A |
| Withdrawn | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small L NCT02662296 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia NCT02530515 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggre NCT02303392 | Jennifer Woyach | Phase 1 |
| Withdrawn | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymp NCT02285244 | James Blachly | Phase 2 |
| Completed | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL NCT02296918 | Acerta Pharma BV | Phase 1 |
| Active Not Recruiting | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic NCT02029443 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Completed | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or NCT02005289 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia NCT02007044 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 NCT01864889 | Chinese PLA General Hospital | N/A |
| Unknown | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory t NCT01735604 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Terminated | Allogeneic Stem Cell Transplant for CLL NCT01629511 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lym NCT01589302 | Kami Maddocks, MD | Phase 2 |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small NCT01515176 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic NCT01212380 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Completed | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01129180 | Pierluigi Porcu | Phase 1 |
| Terminated | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic NCT01126502 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Terminated | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leuk NCT01076556 | National Cancer Institute (NCI) | Phase 1 |
| Completed | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy NCT01029366 | University of Pennsylvania | Phase 1 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemi NCT00735930 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemi NCT00612612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient NCT00719888 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases NCT00309842 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia NCT00098371 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell C NCT00098488 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cel NCT00104858 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With NCT00898079 | Children's Oncology Group | — |
| Completed | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treatin NCT00060424 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Pro NCT00278213 | German CLL Study Group | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia NCT00005786 | National Cancer Institute (NCI) | N/A |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or R NCT00005803 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia NCT00281931 | German CLL Study Group | Phase 2 |